Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.47 |
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9829186 | 1.00 | GPBAR1 (0.47) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL9829516 | 0.94 | NPC1L1 (0.49) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL11778820 | 0.93 | NPC1L1 (0.48) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL11114829 | 0.93 | NPC1L1 (0.42) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL11115189 | 0.93 | NPC1L1 (0.42) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL9172940 | 0.92 | NPC1L1 (0.43) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL10445240 | 0.92 | NPC1L1 (0.43) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL22646212 | 0.92 | NPC1L1 (0.43) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL11431276 | 0.92 | NPC1L1 (0.43) | GPBAR1NPC1L1USP2TP53MEN1 | |
| SCHEMBL26666158 | 0.92 | NPC1L1 (0.43) | GPBAR1NPC1L1USP2TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPBAR1 138/4885NPC1L1 93/4885USP2 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.